Literature DB >> 486288

The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy.

A R Ford, J K Aronson, D G Grahame-Smith, J A Rose.   

Abstract

1 The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes are described. 2 Only one class of binding site can be demonstrated. Binding is time- and temperature-dependent, saturable and slowly reversible; it is inhibited by other cardiac glycosides and by potassium. 3 Pre-incubation with unlabelled digoxin reduces the subsequent binding of 12-alpha-[3H]-digoxin in stoichiometric fashion. 4 The possible application of the measurement of the binding of 12-alpha-[3H]-digoxin to the study of biochemical pharmacological events occurring during digoxin therapy is discussed.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 486288      PMCID： PMC1429769          DOI： 10.1111/j.1365-2125.1979.tb05809.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  14 in total

1.  [Cardiac glycosides as inhibitors of active potassium and sodium transport by erythrocyte membrane].

Authors:  H J SCHATZMANN
Journal:  Helv Physiol Pharmacol Acta       Date:  1953

Review 2.  Membrane adenosinetriphosphatase: a digitalis receptor?

Authors:  T Akera
Journal:  Science       Date:  1977-11-11       Impact factor: 47.728

3.  The sodium-potassium adenosine triphosphatase: pharmacological, physiological and biochemical aspects.

Authors:  A Schwartz; G E Lindenmayer; J C Allen
Journal:  Pharmacol Rev       Date:  1975-03       Impact factor: 25.468

4.  Binding of tritiated digoxin to human red cell ghosts.

Authors:  J C Ellory; R D Keynes
Journal:  Nature       Date:  1969-02-22       Impact factor: 49.962

5.  Binding of the cardiac glycoside ouabain to intact cells.

Authors:  P F Baker; J S Willis
Journal:  J Physiol       Date:  1972-07       Impact factor: 5.182

6.  Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation.

Authors:  A R Ford; J K Aronson; D G Grahame-Smith; J G Carver
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

7.  The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.

Authors:  A R Ford; J K Aronson; D G Grahame-Smith; J G Carver
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

8.  Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.

Authors:  J K Aronson; D G Grahame-Smith; K F Hallis; A Hibble; F Wigley
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

9.  Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution.

Authors:  J K Aronson; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

10.  Quantitative aspects of ouabain binding to human erythrocyte and cardiac membranes.

Authors:  E Erdmann; W Hasse
Journal:  J Physiol       Date:  1975-10       Impact factor: 5.182
View more
  10 in total

1.  Lack of effect of phenytoin on functions related to Na+,K+-ATPase activity of the intact erythrocytes of epileptic patients.

Authors:  J K Aronson; D P Geaney; D G Grahame-Smith; J C Carver; K F Hallis
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

2.  The characteristics of [3H]-ouabain binding to human lymphocytes.

Authors:  K E Pedersen; N A Klitgaard
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

3.  Measurement of specific [3H]-ouabain binding to different types of human leucocytes.

Authors:  N A Boon; V M Oh; E A Taylor; T Johansen; J K Aronson; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

4.  The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.

Authors:  A R Ford; J K Aronson; D G Grahame-Smith; J G Carver
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

5.  Cardiac glycoside-mediated turnover of Na, K-ATPases as a rational approach to reducing cell surface levels of the cellular prion protein.

Authors:  Mohadeseh Mehrabian; Xinzhu Wang; Shehab Eid; Bei Qi Yan; Mark Grinberg; Murdock Siegner; Christopher Sackmann; Muhammad Sulman; Wenda Zhao; Declan Williams; Gerold Schmitt-Ulms
Journal:  PLoS One       Date:  2022-07-01       Impact factor: 3.752

6.  Erythrocytic cation transport receptor numbers and activity in pregnancies complicated by essential hypertension and pre-eclampsia.

Authors:  J K Aronson; M P Moore; C W Redman; C Harper
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-05

7.  Influence of digitalis and diuretics on ouabain binding sites on human erythrocytes.

Authors:  E Erdmann; K Werdan; W Krawietz
Journal:  Klin Wochenschr       Date:  1984-01-16

8.  Ouabain inhibition of the sodium-potassium pump: estimation of ED50 in different types of human leucocytes in vitro.

Authors:  B Møller; A Vaag; T Johansen
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

9.  Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own erythrocytes during glycoside therapy.

Authors:  J K Aronson; A R Ford; D G Grahame-Smith
Journal:  Klin Wochenschr       Date:  1981-12-15

10.  Erythrocyte Na+, K+-ATPase and serum digoxin concentrations.

Authors:  A H From; G J Quarfoth; B W Steele; K Ahmed
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.